Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer's disease.
Borislav Dejanovic, Matthew D Figley, Elizabeth Weisman et al.
✦ AI-curated · Sources linked
In 30 seconds
This study evaluated VG-3927, an oral, CNS-penetrant small-molecule TREM2 agonist, using preclinical models and a first-in-human randomized, double-blind, placebo-controlled phase 1 trial. Preclinical experiments reported TREM2 signaling and microglial effects, including increased amyloid-β phagocytosis in a mouse model. In the trial, 115 participants received single or multiple ascending doses of up to 140 milligrams; the drug was well tolerated and showed a CSF-to-unbound plasma ratio of 0.91. Dose-dependent reductions in CSF sTREM2 supported target engagement and further clinical development.
Key findings
- In the phase 1 trial (n = 115), VG-3927 was well tolerated at single and multiple ascending doses of up to 140 milligrams.
- The CSF-to-unbound plasma ratio was 0.91, supporting high CNS penetration and once-daily dosing.
- CSF sTREM2 decreased dose-dependently, with the biomarker response reported across healthy and elderly participants and participants with AD.
- In 5xFAD mice expressing common-variant human TREM2, VG-3909 enhanced amyloid-β phagocytosis and altered microglial transcription.
Why it matters
TREM2 is implicated in microglial function and late-onset AD risk, but translating target engagement into clinical benefit remains an important challenge. These findings provide early human evidence that an oral small molecule can reach the CNS and engage TREM2, alongside supportive preclinical results. They establish a rationale for further clinical evaluation, not evidence of efficacy in AD.
What to keep in mind
The human evidence is from a phase 1 trial focused on tolerability, pharmacokinetics, and a target-engagement biomarker; the abstract reports no clinical efficacy outcomes.